LOTTE Biologics, with its co-CEO James Park as well as Yoo-yeol Shin,ย announced a key commercial manufacturing contract with a global pharmaceutical company on November 17, 2026, representing a major step in the commercialization of its Songdo Bio Campus.
The pact is the first significant commercial manufacturing deal for Songdo Plant 1, which was signed even before its operations began. LOTTE Biologics will offer integrated drug substance along with drug product manufacturing services to support major products in the customerโs standard product line under the agreement, with commercial production planned to start in 2027.
Growth strategy validated by early commercial success
The signing of this key commercial manufacturing contract by LOTTE during the facility development phase demonstrates consumer trust in theย technical expertise, implementation performance, and long-term supply dependability of LOTTE Biologics.
LOTTE Biologics is speeding up its journey to commercialization and building a solid foundation for sustainable development, syncingย capacity expansion with customer objectives from the very beginning.
Advanced Infrastructure Designed for Global Biologics Production
Songdo Plant 1 has been developed to satisfy the changing demands of global biopharmaceutical manufacturing and is equipped with cutting-edge production facilities, sophisticated automation, and massive cold-chain warehousing to enable effective, dependable, and quality-focused operations.
The Songdo Bio Campus is being constructed with an overall capacity of 360,000 liters distributed among three plants, with Plant 1 offering a capacity of 120,000 liters in 8 stainless-steel bioreactors of 15,000 liters each.
The facility will be an addition to theย Syracuse Bio Campus from LOTTE Biologicsย in New York, which has over twenty years of manufacturing experience, a proven record of facilitating more thanย 62 regulatory authorizations, and a recent FDA evaluation with no observations.
Together they create an integrated global manufacturing network built to provide operational adaptability, uniform quality requirements, and enhanced supply chain resilience.
Creating a Differentiated Global CMO
LOTTE Biologics is emerging as a viable ally for global biologics manufacturing as pharmaceutical firms look for reputable manufacturing collaborators with established execution standards and geographically diverse supply networks.
The latest agreement is a concrete step in the direction of that goal, converting strategic investments into commercial obligations and bolstering the long-term growth path of the company.
According to Co-CEO of LOTTE Biologics, James Park, “This agreement is a strong endorsement of our strategy and the confidence our customers place in LOTTE Biologics. We are not simply building manufacturing capacity. We are building a globally integrated platform designed to deliver quality, reliability, and speed. By combining Syracuseโs proven expertise with Songdoโs advanced infrastructure, we are well positioned to support our partnersโ success and bring life-changing medicines to patients worldwide.โ

